Drugs / CNM-Au8
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials · 1 missed | ||||||
| Phase 2 | NCT05299658 | Nov 2021 → Jun 2026 overdue | amyotrophic lateral sclerosis | Clene Nanomedicine | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04098406 | Dec 2019 → Jul 2021 | amyotrophic lateral sclerosis | Clene Nanomedicine | Completed | Missed primary |
| Phase 2 | NCT03536559 | Nov 2018 → Apr 2022 | optic neuritis, relapsing-remitting multiple sclerosis | Clene Nanomedicine | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2/33 trials · 2 missed | ||||||
| Phase 2/3 | NCT04626921 | Oct 2020 → May 2023 | multiple sclerosis | Clene Nanomedicine | Completed | No outcome recorded |
| Phase 2/3 | NCT04414345 | Jul 2020 → Apr 2022 | amyotrophic lateral sclerosis | Merit E. Cudkowicz, MD | Completed | Missed primary |
| Phase 2/3 | NCT04297683 | Jun 2020 → Jul 2027 expected | amyotrophic lateral sclerosis | Merit E. Cudkowicz, MD | Recruiting | Missed primary |
| Phase not stated3 trials | ||||||
| — | NCT06408727 | — | amyotrophic lateral sclerosis | Clene Nanomedicine | Temporarily not available | No outcome recorded |
| — | NCT04081714 | — | multiple sclerosis | Clene Nanomedicine | Temporarily not available | No outcome recorded |
| — | NCT05281484 | — | amyotrophic lateral sclerosis | Clene Nanomedicine | No longer available | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-09-08 | Quantum Biopharma | Results A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach issuerdirect.com ↗
Clene Inc. (NASDAQ: CLNN) shared results from new analyses examining clinical outcomes among CNM-Au8(R)-treated patients whose neurofilament light chain (“NfL”) biomarker levels declined or stabilized. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-09-08 | Quantum Biopharma | A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach issuerdirect.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CNM-Au8 | “CNM-Au8® is a catalytically-active gold nanocrystal neuroprotective agent” PMID 37396808 ↗ Jun 2023 |
| Modality | Other / unclassified | “CNM-Au8 is an aqueous suspension of clean surfaced faceted nanocrystals consisting of gold atoms self-organized into crystals of various geometrical shapes” NCT04081714 ↗ |
| Route | Oral | “The drug product is formulated to be taken orally” NCT03536559 ↗ |